Bicara Therapeutics Inc. (BCAX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $939.94M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-567.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $929.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-243.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $7.00K; Additional Paid in CapitalUSD $760.17M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $243.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $7.00K; Additional Paid in CapitalUSD $724.49M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-136.00K.
Bicara Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $8.00K | $939.94M | $-567.00K | $-470.61M | $468.77M | 3 month · $8.24M |
| 2026-03-31 | $0.00 | $8.00K | $929.37M | $-243.00K | $-415.18M | $513.96M | 3 month · $5.86M |
| 2025-12-31 | $0.00 | $7.00K | $760.17M | $243.00K | $-358.97M | $401.45M | 12 month · $15.01M |
| 2025-09-30 | $0.00 | $7.00K | $724.49M | $-136.00K | $-321.58M | $402.78M | 3 month · $3.61M |
| 2025-06-30 | $0.00 | $7.00K | $720.44M | (m) | $-285.25M | $435.20M | 3 month · $3.49M |
| 2025-03-31 | $0.00 | $7.00K | $716.81M | (m) | $-257.86M | $458.96M | 3 month · $3.45M |
| 2024-12-31 | $0.00 | $7.00K | $712.88M | $0.00 | $-221.02M | $491.88M | 12 month · $7.40M |
| 2024-09-30 | $0.00 | $7.00K | $709.61M | (m) | $-200.06M | $509.56M | 3 month · $2.03M |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | $-174.78M | 3 month · $1.04M |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | $-160.08M | 3 month · $1.15M |
| 2023-12-31 | $0.00 | $2.00K | $4.25M | (m) | $-153.02M | $-148.77M | 12 month · $1.90M |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $-137.11M | 3 month · $519.00K |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-114.82M | 3 month · $352.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-105.91M | 3 month · $264.00K |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $-98.80M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |